-
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Needham & Company LLC
Source: Buzz FX / 13 Feb 2025 07:21:11 America/New_York
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Needham & Company LLC Written by MarketBeat February 13, 2025 Share Link copied to clipboard. Needham & Company LLC reaffirmed their buy rating on shares of CRISPR Therapeutics ( NAS
Read more...